Glomus vagale tumors

A hereditary autosomal dominant condition characterized by glomus tumors that are similar to mucocutaneous venous malformations (OMIM: 600195), but have a cobble-stone appearance, harder consistency, and are painful on palpation. Histologically, they are distinguishable by the presence of pathognomonic rounded cells (glomus cells) around the distended vein-like channels. Glomus cells in glomuvenous malformations stain positively for smooth muscle cell alpha-actin (ACTA2) and VIMENTIN. Mutations in the GLML gene have been identified. OMIM: 138000

Also Known As:

Networked: 13 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Multiple Cutaneous and Mucosal Venous Malformations
2.	Central Nervous System Cavernous Hemangioma
3.	Klippel-Trenaunay-Weber Syndrome (Syndrome, Klippel-Trenaunay-Weber)
4.	Retinal Telangiectasis
5.	Vascular Malformations

Experts

1.	Alegre-Sanchez, Adrian: 1 article (12/2018)
2.	Boixeda, Pablo: 1 article (12/2018)
3.	Fonda, Pablo: 1 article (12/2018)
4.	Jimenez, Natalia: 1 article (12/2018)
5.	Moreno-Arrones, Oscar Muñoz: 1 article (12/2018)
6.	Buckley, Colin: 1 article (09/2015)
7.	Smidt, Aimee C: 1 article (09/2015)
8.	Trost, Jaren: 1 article (09/2015)
9.	Ashida, Hiroshi: 1 article (10/2014)
10.	Franchi, Luigi: 1 article (10/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Glomus vagale tumors:

1.	Cullin Proteins (Cullins)IBA 10/07/2014 - "This protein originally was identified through its association with glomuvenous malformations and more recently was described as a member of a Cullin ring ligase inhibitor. "
2.	TIE-2 Receptor (Receptor, TIE 2)IBA 08/01/2006 - "However, due to detailed analysis inherited forms have been observed, which has led to identify mutations in three genes causing familial vascular malformations: in the angiopoietin receptor TIE2 in mucocutaneous venous malformations (VMCM), in glomulin in glomuvenous malformations (GVM) and in RASA1 in the newly recognized phenotype capillary malformation-arteriovenous malformation (CM-AVM). "
3.	AngiopoietinsIBA 08/01/2006 - "However, due to detailed analysis inherited forms have been observed, which has led to identify mutations in three genes causing familial vascular malformations: in the angiopoietin receptor TIE2 in mucocutaneous venous malformations (VMCM), in glomulin in glomuvenous malformations (GVM) and in RASA1 in the newly recognized phenotype capillary malformation-arteriovenous malformation (CM-AVM). "
4.	Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA 01/01/2005 - "These genes include AGGF1 for Klippel-Trenaunay syndrome, RASA1 for capillary malformations, KRIT1, MGC4607, PDCD10 for cerebral cavernous malformations, glomulin for glomuvenous malformations, TIE2 for multiple cutaneous and mucosal venous malformations, VEGFR-3, FOXC2, NEMO, SOX18 for lymphedema or related syndromes, ENG, ACVRLK1, MADH4 for HHT or related syndromes, NDP for Coats' disease, Notch3 for CADASIL, and PTEN for Proteus Syndrome. "
5.	Activins (Activin)IBA 04/15/2002 - "Homozygosity mapping excluded the following loci and/or genes: multiple cutaneous venous malformation (VMCM1; gene, TIE2) on chromosome 9p21; venous malformation with glomus cells (VMGLOM) on chromosome 1p22-p21; hereditary hemorrhagic telangiectasia type 1 (HHT1; gene, endoglin) and type 2 (HHT2; gene, activin) on chromosomes 9q34.1 and 12q11-q14, respectively; and cerebral cavernous malformation type 1 (CCM1; gene, KRIT1), type 2 (CCM2), and type 3 (CCM3) on chromosomes 7q11.2-q21, 7p15-p13, and 3q35.2-q27, respectively. "
6.	Proteins (Proteins, Gene)FDA Link 10/07/2014 - "This protein originally was identified through its association with glomuvenous malformations and more recently was described as a member of a Cullin ring ligase inhibitor. "
7.	Ligases (Synthetase)IBA 10/07/2014 - "This protein originally was identified through its association with glomuvenous malformations and more recently was described as a member of a Cullin ring ligase inhibitor. "
8.	DNA (Deoxyribonucleic Acid)IBA 08/01/2007 - "We analysed the DNA of one family with hereditary glomuvenous malformations and identified the mutation causing the disease in the glomulin gene on chromosome 1 p22. "
9.	Polidocanol (Laureth)FDA Link 01/01/2022 - "Polidocanol has shown efficacy in the treatment of mucocele of minor salivary gland, hemangioma, upper extremity veins, reticular veins of the chest, facial veins, pyogenic granuloma, lymphangioma circumscriptum, digital mucous cyst, mixed skin ulcers, cutaneous focal mucinosis, seromas, glomuvenous malformations, acne cysts, lymphocele, and dissecting cellulitis. "
10.	EndoglinIBA 04/15/2002 - "Homozygosity mapping excluded the following loci and/or genes: multiple cutaneous venous malformation (VMCM1; gene, TIE2) on chromosome 9p21; venous malformation with glomus cells (VMGLOM) on chromosome 1p22-p21; hereditary hemorrhagic telangiectasia type 1 (HHT1; gene, endoglin) and type 2 (HHT2; gene, activin) on chromosomes 9q34.1 and 12q11-q14, respectively; and cerebral cavernous malformation type 1 (CCM1; gene, KRIT1), type 2 (CCM2), and type 3 (CCM3) on chromosomes 7q11.2-q21, 7p15-p13, and 3q35.2-q27, respectively. "

Therapies and Procedures

1.	Lasers (Laser) 09/01/2015 - "Currently there exist few reported cases where lasers are used successfully to treat glomuvenous malformations in adolescents. " 06/01/2007 - "Laser treatment of mucosa and tongue was done with a mean fluence of 103.1 J/cm(2), of skin with 90.7 J/cm(2), and of glomuvenous malformations with 81.2 J/cm(2). "
2.	Solid-State Lasers 12/01/2018 - "Glomuvenous malformations: dual PDL-Nd:YAG laser approach." 09/01/2015 - "Long-Pulsed Neodymium-Doped Yttrium Aluminum Garnet Laser for Glomuvenous Malformations in Adolescents." 01/01/2014 - "Plaque-type glomuvenous malformations successfully treated using combined pulsed dye laser and neodymium-doped yttrium aluminum garnet laser."
3.	Dye Lasers 01/01/2014 - "Plaque-type glomuvenous malformations successfully treated using combined pulsed dye laser and neodymium-doped yttrium aluminum garnet laser."
4.	Sclerotherapy 12/01/2011 - "Seventy-nine sclerotherapy procedures were performed on 44 patients with 37 venous malformations, 2 glomuvenous malformations, 2 lymphatic malformations, 2 lymphatico-venous malformations, and 1 Klippel-Trenaunay syndrome. "
5.	Therapeutics 01/01/1993 - "Surgical therapy of glomus vagale tumors."